A Safety Study of Lactobacillus Reuteri BGP-014 in Patients With Ulcerative Colitis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

35 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-02-09

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objectives of this study are to evaluate the safety, tolerability and preliminary efficacy of Lactobacillus reuteri BGP-014 in mild to moderate active Ulcerative Colitis (UC) patients as an oral administered local treatment in addition to Standard of Care (SoC) treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Research on the Use of Probiotics in the Prevention and Treatment of Inflammatory Bowel Disease

NCT06781827

Inflammatory Bowel Disease

RECRUITING NA

Effect of Lactobacillus Casei DG (Enterolactis Plus®) in Patient With Irritable Bowel Syndrome: a Pilot Study

NCT02371499

Irritable Bowel Syndrome

COMPLETED NA

The Efficacy of Single-strain Probiotics in Patients With Irritable Bowel Syndrome

NCT05064930

Irritable Bowel Syndrome

COMPLETED NA

Lactobacillus LB as Treatment for Irritable Bowel Syndrome With Predominance of Diarrhea (IBS-D)

NCT04053790

Irritable Bowel Syndrome With Diarrhea

COMPLETED PHASE4

Probiotics in GastroIntestinal Disorders

NCT00510978

Ulcerative Colitis Crohn's Disease

UNKNOWN PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ulcerative Colitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active

Group Type EXPERIMENTAL

BGP-014

Intervention Type BIOLOGICAL

Oral capsule containing lyophilised Lactobacillus reuteri

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type BIOLOGICAL

Oral capsule

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BGP-014

Oral capsule containing lyophilised Lactobacillus reuteri

Intervention Type BIOLOGICAL

Placebo

Oral capsule

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The subject has given written consent to participate in the study.
* Diagnosed previously with UC (\> 6 months earlier) determined by clinical and endoscopic histopathology (pathology showing chronic inflammatory changes). ≥1 documented previous flare-up and with last resolved flare \>3 months away.
* Active UC determined by sigmoidoscopy before randomisation of study (baseline) and defined as a total Mayo index score of 4 to 10 points (endoscopic subscore ≥1, rectal bleeding ≥1).
* Permitted concomitant SoC medications include: Oral aminosalicylates (5-ASA), with a stable dose (1.6-4.8g/ day) for at least 12 days prior to screening, Visit 1. Steroids (dose ≤15mg at screening, Visit 1) with further tapering of dose in accordance with SoC until steroid tx termination. Immunomodulator, as: 6-Mercaptopurine, Azathioprine, Methotrexate (Stable dose for \> 12 weeks prior to screening, Visit 1).
* Females of childbearing potential must use effective contraceptives

Exclusion Criteria

1. Involvement in any investigational drug or device study within 30 days prior to this study
2. Known intolerance of 5-ASA or sulphasalazine medications
3. Biologics or FMT treatment less than 12 weeks before screening
4. No 5-ASA or steroid topical treatment is allowed
5. Antibiotic treatment \< 1 month prior the study
6. Unable to maintain stable dose of NSAIDs and PPIs
7. Evidence of on-going extensive colitis
8. Fever, defined as a temperature of \>38.5 °C, at Visit 1
9. Anaemia, Hb value below 100
10. Evidence of on-going toxic megacolon
11. Presence of obstructive diseases of the gastrointestinal system
12. Any clinically significant concomitant disease that might interfere with patient safety
13. Unwilling to withdraw probiotic supplements. Yoghurts without supplemented bacteria are permitted
14. Pregnant
15. Planned abdominal surgery
16. Judged unable by the physician to comprehend information regarding the study

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No